Exploring Apr 24 2026 This Week In Cardiology
Let's dive into the details surrounding Apr 24 2026 This Week In Cardiology.
- A life-long treatment for high LDL, a VESALIUS subanalysis, tirzepatide beats semaglutide again, arrhythmia burden in
- Listener feedback from the DanGer Shock investigators, complete vs staged revascularization, polygenic risk scores, and quality ...
- Three imaging-guided PCI trials (two with surprising results), LDL targets, an oral PCSK9 inhibitor, and another beta-blocker ...
- Listener feedback on ICE vs TEE in AF ablation, fractional flow reserve without a wire or catheter, more bad news for ticagrelor, ...
- Listener feedback, the value of procedural volume for TAVR and MTEER, ventricular arrhythmia in older athletes, and the ...
In-Depth Information on Apr 24 2026 This Week In Cardiology
PCSK9 inhibitors in high-risk diabetes without ASCVD, the CAAN-AF trial, conduction system pacing vs biventricular pacing, PFA ... John Mandrola offers an ACC recap of 5 big trials—Hi-PEITHO, PROTAVI, ORBITA-CTO, CHIPS-BCIS3 and CHAMPION AF This ... DAPT back in the news, a practice-changing trial in VTE therapy, new knowledge in sudden SPIRIT-HF, another spironolactone trial in HFpEF; the ESSENCE imaging study of the drug olezarsen; the SirPAD trial in ...
Early aortic valve replacement in aortic stenosis, left atrial appendage occlusion in JAMA
That wraps up our extensive overview of Apr 24 2026 This Week In Cardiology.